Aquestive(US:AQST) Globenewswire·2026-03-12 12:24Core Viewpoint - A securities fraud class action lawsuit has been initiated against Aquestive Therapeutics, Inc. for alleged misrepresentations regarding its New Drug Application for Anaphylm (Dibutepinephrine) sublingual film, affecting investors who purchased securities between June 16, 2025, and January 8, 2026 [5][6]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the District of New Jersey on behalf of investors who acquired Aquestive securities during the specified period [5]. - The allegations include violations of the Securities Exchange Act of 1934 against the Company and certain senior officers [5]. Group 2: Investor Actions - Investors who purchased or acquired Aquestive securities are encouraged to discuss their legal rights and options, with a deadline to file as lead plaintiff by May 4, 2026 [3][4]. - All representation in the lawsuit is on a contingency fee basis, meaning shareholders will not incur fees or expenses [4]. Group 3: Law Firm Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since its inception in 1993 and has a strong track record in class action litigation [7].